Comparison of tadalafil monotherapy and its combination with mirabegron for efficacy in the treatment of storage symptoms with benign prostatic hyperplasia
Not Applicable
Recruiting
- Conditions
- Benign prostatic hyperplasia
- Registration Number
- JPRN-UMIN000030560
- Lead Sponsor
- Division of Urology, Department of Surgery, Tottori University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 120
Inclusion Criteria
Not provided
Exclusion Criteria
Study exclusion criteria are post-void residual urine volume greater than 100 ml, acute urinary retention, neurogenic bladder dysfunction, severe bladder diverticulum or urethral stricture, urinary tract malignant disease, previous intrapelvic irradiation, renal or hepatic impairment, severe cardiac disease, or considered unsuitable for the trial by doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overactive bladder symptom score (OABSS)
- Secondary Outcome Measures
Name Time Method umber of night urination International prostate symptom score Overactive bladder-questionnaire (OAB-q) Nocturia-quality of life (N-QOL)